Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Envafolimab plus platinum-based chemotherapy in resectable stage II–III NSCLC
ChiCTR2600127714Phase 4Recruiting
- Sponsor
- Aerospace Center Hospital
- Start
- Jul 2026
- Modality
- Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of envafolimab in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Aerospace Center Hospital. Primary endpoint: Major pathological response. Started Jul 2026; status: recruiting.
02
Drugs
envafolimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2600127714.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600127714.